Top

Published in:

01-12-2005

Can the Memorial Sloan-Kettering Cancer Center Nomogram Predict the Likelihood of Nonsentinel Lymph Node Metastases in Breast Cancer Patients in The Netherlands?

Authors: Marjolein L. Smidt, MD, Deborah M. Kuster, MD, Gert Jan van der Wilt, PhD, Frederik B. Thunnissen, MD, PhD, Kimberley J. Van Zee, MD, Luc J. A. Strobbe, MD, PhD

Published in: Annals of Surgical Oncology | Issue 12/2005

Abstract

Background

According to Dutch guidelines, an axillary lymph node dissection (ALND) is recommended whenever a sentinel lymph node (SLN) contains metastatic disease. However, only in approximately 50% of patients with metastatic disease in the SLN are additional nodal metastases detected in the completion ALND. To identify the individual patient’s risk for non-SLN metastases, a nomogram containing eight predictors was developed by the Breast Service of Memorial Sloan-Kettering Cancer Center (New York, NY). The aim of this study was to test the accuracy of the nomogram on a population of Dutch breast cancer patients.

Methods

Patient, tumor, and SLN metastasis characteristics were collected for 222 consecutive patients who underwent a completion ALND. The data of the index and test populations were compared. A receiver operating characteristic curve was drawn, and the area under the curve was calculated to assess the discriminative power of the nomogram.

Results

Even though our patient population differed in many respects from the source population, the area under the receiver operating characteristic curve amounted to .77, a value very much comparable to the one found in the source population.

Conclusions

The nomogram provides a fairly accurate predicted probability for the likelihood of non-SLN metastases in a general population of breast cancer patients at a regional teaching hospital in The Netherlands. This suggests that the nomogram’s originally calculated predictive accuracy may be valid for patient populations that differ considerably from the population in which it was developed.

Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 1983;52:1551–6PubMed

Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997;226:271–7CrossRefPubMed

Veronesi U. The sentinel node and breast cancer. Br J Surg 1999;86:1–2CrossRefPubMed

Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997;349:1864–7CrossRefPubMed

Giuliano AE, Haigh PI, Brennan MB, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000;18:2553–9PubMed

Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer—a multicenter validation study. N Engl J Med 1998;339:941–6CrossRefPubMed

O’Hea BJ, Hill AD, El Shirbiny AM, et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 1998;186:423–7PubMed

Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349:546–53CrossRefPubMed

Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674–81PubMed

10.

Greco M, Agresti R, Cascinelli N, et al. Breast cancer patients treated without axillary surgery: clinical implications and biologic analysis. Ann Surg 2000;232:1–7CrossRefPubMed

11.

Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival—a Bayesian meta-analysis. Ann Surg Oncol 1999;6:109–16CrossRefPubMed

12.

Harris JR, Osteen RT. Patients with early breast cancer benefit from effective axillary treatment. Breast Cancer Res Treat 1985;5:17–21PubMed

13.

Moore MP, Kinne DW. Axillary lymphadenectomy: a diagnostic and therapeutic procedure. J Surg Oncol 1997;66:2–6CrossRefPubMed

14.

American Joint Committee on Cancer. Breast. In: AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag, 2002:221–40

15.

Cady B. Case against axillary lymphadenectomy for most patients with infiltrating breast cancer. J Surg Oncol 1997;66:7–10CrossRefPubMed

16.

Weiser MR, Montgomery LL, Tan LK, et al. Lymphovascular invasion enhances the prediction of non-sentinel node metastases in breast cancer patients with positive sentinel nodes. Ann Surg Oncol 2001;8:145–9PubMed

17.

Fant JS, Grant MD, Knox SM, et al. Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection. Ann Surg Oncol 2003;10:126–30CrossRefPubMed

18.

Rouzier R, Extra JM, Klijanienko J, et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002;20:1304–10CrossRefPubMed

19.

Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2003;10:1140–51CrossRefPubMed

20.

Abdessalam SF, Zervos EE, Prasad M, et al. Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer. Am J Surg 2001;182:316–20CrossRefPubMed

21.

Bevilacqua J, Cody H, MacDonald KA, Tan LK, Borgen PI, Van Zee KJ. A prospective validated model for predicting axillary node metastases based on 2,000 sentinel node procedures: the role of tumour location. Eur J Surg Oncol 2002;28:490–500PubMed

22.

Chu KU, Turner RR, Hansen NM, Brennan MB, Bilchik A, Giuliano AE. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 1999;229:536–41CrossRefPubMed

23.

Grube BJ, Hansen NM, Ye X, Giuliano AE. Tumor characteristics predictive of sentinel node metastases in 105 consecutive patients with invasive lobular carcinoma. Am J Surg 2002;184:372–6CrossRefPubMed

24.

Hwang RF, Krishnamurthy S, Hunt KK, et al. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol 2003;10:248–54PubMed

25.

Port ER, Tan LK, Borgen PI, Van Zee KJ. Incidence of axillary lymph node metastases in T1a and T1b breast carcinoma. Ann Surg Oncol 1998;5:23–7PubMed

26.

Rahusen FD, Torrenga H, Van Diest PJ, et al. Predictive factors for metastatic involvement of nonsentinel nodes in patients with breast cancer. Arch Surg 2001;136:1059–63PubMed

27.

Sachdev U, Murphy K, Derzie A, Jaffer S, Bleiweiss IJ, Brower S. Predictors of nonsentinel lymph node metastasis in breast cancer patients. Am J Surg 2002;183:213–7CrossRefPubMed

28.

Travagli JP, Atallah D, Mathieu MC, et al. Sentinel lymphadenectomy without systematic axillary dissection in breast cancer patients: predictors of non-sentinel lymph node metastasis. Eur J Surg Oncol 2003;29:403–6CrossRefPubMed

29.

Viale G, Maiorano E, Mazzarol G, et al. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer 2001;92:1378–84CrossRefPubMed

30.

Kamath VJ, Giuliano R, Dauway EL, et al. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Arch Surg 2001;136:689–92

31.

Degnim AC, Griffith KA, Sabel MS, et al. Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer 2003;98:2307–15CrossRefPubMed

32.

Specht MC, Kattan MW, Gonen M, Fey J, Van Zee KJ. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol 2005;12:654–9CrossRefPubMed

33.

Smidt ML, Janssen CMM, Kuster DM, Bruggink EDM, Strobbe LJA. Axillary recurrence after a negative sentinel node biopsy for breast cancer: incidence and clinical significance. Ann Surg Oncol 2005;12:29–33CrossRefPubMed

Title: Can the Memorial Sloan-Kettering Cancer Center Nomogram Predict the Likelihood of Nonsentinel Lymph Node Metastases in Breast Cancer Patients in The Netherlands?
Authors: Marjolein L. Smidt, MD
Deborah M. Kuster, MD
Gert Jan van der Wilt, PhD
Frederik B. Thunnissen, MD, PhD
Kimberley J. Van Zee, MD
Luc J. A. Strobbe, MD, PhD
Publication date: 01-12-2005
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 12/2005
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/ASO.2005.07.022

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Can the Memorial Sloan-Kettering Cancer Center Nomogram Predict the Likelihood of Nonsentinel Lymph Node Metastases in Breast Cancer Patients in The Netherlands?

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2005

Detection of Carcinoembryonic Antigen Messenger RNA–Expressing Cells in Portal and Peripheral Blood During Surgery Does Not Influence Relapse in Colorectal Cancer

Inadequacy of Lymph Node Staging in Gastric Cancer Patients: A Population-Based Study

The Surgical and Functional Outcome of Limb-Salvage Surgery With Vascular Reconstruction for Soft Tissue Sarcoma of the Extremity

Effectiveness of Palliative Procedures for Intra-Abdominal Sarcomas

Evaluation of Intraoperative Autotransfusion Filtration for Hepatectomy and Pancreatectomy

Herpes Simplex Virus Amplicon Delivery of a Hypoxia-Inducible Soluble Vascular Endothelial Growth Factor Receptor (sFlk-1) Inhibits Angiogenesis and Tumor Growth in Pancreatic Adenocarcinoma